$0.89-5.1%Nov 12 close
Figures through September 30, 2026, from the 6-K filed November 12, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Profit | -$2.1M | -$863.7K | -146.09% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“NuCana’s priorities are to define the next stage of clinical development for NUC-7738 in melanoma following the anticipated December announcement of the Phase 2 NuTide:701 expansion study results and latest translational data,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
The quote and the company description come from the 6-K Nucana plc filed on November 12, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Nucana plc reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.